AU2012340621B2 - Administration of alpha4beta7 hetero-dimer-specific antibody - Google Patents

Administration of alpha4beta7 hetero-dimer-specific antibody Download PDF

Info

Publication number
AU2012340621B2
AU2012340621B2 AU2012340621A AU2012340621A AU2012340621B2 AU 2012340621 B2 AU2012340621 B2 AU 2012340621B2 AU 2012340621 A AU2012340621 A AU 2012340621A AU 2012340621 A AU2012340621 A AU 2012340621A AU 2012340621 B2 AU2012340621 B2 AU 2012340621B2
Authority
AU
Australia
Prior art keywords
antibody
days
seq
cdr2
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012340621A
Other languages
English (en)
Other versions
AU2012340621A1 (en
Inventor
Dominique BORIE
Hailing Hsu
Wei-jian PAN
William Rees
Barbara Sullivan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2012340621A1 publication Critical patent/AU2012340621A1/en
Application granted granted Critical
Publication of AU2012340621B2 publication Critical patent/AU2012340621B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2012340621A 2011-11-23 2012-11-21 Administration of alpha4beta7 hetero-dimer-specific antibody Active AU2012340621B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161563430P 2011-11-23 2011-11-23
US61/563,430 2011-11-23
US201261599221P 2012-02-15 2012-02-15
US61/599,221 2012-02-15
PCT/US2012/066345 WO2013078375A2 (en) 2011-11-23 2012-11-21 Administration of alpha4beta7 hetero-dimer-specific antibody

Publications (2)

Publication Number Publication Date
AU2012340621A1 AU2012340621A1 (en) 2014-05-29
AU2012340621B2 true AU2012340621B2 (en) 2017-10-12

Family

ID=47291275

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012340621A Active AU2012340621B2 (en) 2011-11-23 2012-11-21 Administration of alpha4beta7 hetero-dimer-specific antibody

Country Status (7)

Country Link
US (1) US9914779B2 (enExample)
EP (2) EP2782599B1 (enExample)
JP (2) JP6203740B2 (enExample)
AU (1) AU2012340621B2 (enExample)
CA (1) CA2856866C (enExample)
MX (1) MX366936B (enExample)
WO (1) WO2013078375A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2890600T3 (es) 2014-05-16 2022-01-20 Protagonist Therapeutics Inc Péptidos de tioéter antagonistas de integrina alfa4beta7
CA3154741A1 (en) * 2019-09-20 2021-03-25 University Of Florida Research Foundation, Incorporated Detection of antibodies against ran proteins from serum and tissue lysates
BR112022013628A2 (pt) * 2020-01-10 2022-11-22 Protagonist Therapeutics Inc Métodos para tratar doenças inflamatórias intestinais com antagonistas de integrina alpha-4 beta-7
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN116482345B (zh) * 2023-06-16 2023-09-22 军科正源（北京）药物研究有限责任公司 用于检测双靶点药物受体占有率的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078779A2 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease
WO2010107752A2 (en) * 2009-03-20 2010-09-23 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY162179A (en) * 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
JP2010521966A (ja) 2007-03-20 2010-07-01 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリンに結合するヒト化免疫グロブリンをコードする核酸
KR101361905B1 (ko) * 2008-05-16 2014-02-21 제넨테크, 인크. 베타7 인테그린 길항제를 이용한 위장관 염증 장애의 치료를 평가하기 위한 바이오마커의 용도
EA201891433A3 (ru) 2010-01-15 2019-02-28 Кирин-Эмджен, Инк. Состав антитела и терапевтические режимы

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078779A2 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease
WO2010107752A2 (en) * 2009-03-20 2010-09-23 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FEAGAN, BG et al., 'Treatment of Active Crohn's Disease with MLN0002, a Humanized Antibody to the a4ß7 Integrin,' Clinical Gastroenterology and Hepatology, (2008), vol 6, pp 1370-1377. *
FEAGAN, BG et al., 'Treatment of Ulcerative Colitis with a Humanized Antibody to the a4ß7 Integrin,' The New England Journal of Medicine, (2005), vol 352, No 24, pp2499-2507. *

Also Published As

Publication number Publication date
US20140322209A1 (en) 2014-10-30
WO2013078375A2 (en) 2013-05-30
JP6564435B2 (ja) 2019-08-21
US9914779B2 (en) 2018-03-13
MX366936B (es) 2019-07-31
EP2782599B1 (en) 2019-10-16
WO2013078375A3 (en) 2013-10-03
EP2782599A2 (en) 2014-10-01
CA2856866A1 (en) 2013-05-30
JP2018031780A (ja) 2018-03-01
EP3492099A1 (en) 2019-06-05
CA2856866C (en) 2022-07-12
JP2015505822A (ja) 2015-02-26
AU2012340621A1 (en) 2014-05-29
JP6203740B2 (ja) 2017-09-27
MX2014006265A (es) 2014-10-24

Similar Documents

Publication Publication Date Title
TWI857389B (zh) 治療發炎症狀的方法
CA3116725C (en) Secukinumab for use in the treatment of psoriatic arthritis
AU2017218919A1 (en) Dosage Regimen For Administering A CD19XCD3 Bispecific Antibody To Patients At Risk For Potential Adverse Effects
JP6564435B2 (ja) アルファ４ベータ７ヘテロ二量体特異抗体の投与
JP2020073470A (ja) 抗ｉｌ２３抗体を使用してクローン病を治療するための方法
JP2017522043A (ja) ＦｃＲｎ特異的ヒト抗体及びこれを含む自己免疫疾患治療用組成物
JP7042816B2 (ja) レプチン受容体をアンタゴナイズする抗原結合性タンパク質
AU2020230333A1 (en) Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers
JP2017510627A (ja) 多発性硬化症の併用治療
US12440561B2 (en) Method of diagnosis and treatment of rheumatoid arthritis
EA037027B1 (ru) Применение и способ для профилактики или лечения рака желудка с использованием композиции, содержащей моноклональное прогастринсвязывающее антитело
JP6450594B2 (ja) プレセプシン測定による炎症性腸疾患の診断
KR20230019196A (ko) Il-18에 대한 항체를 포함하는 방법 및 치료
JP2023523096A (ja) 急性呼吸促迫症候群を治療するための組成物および方法
US20110104153A1 (en) Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients
AU2010286427A1 (en) Use of an immunoregulatory NK cell population for monitoring the efficacy of anti-IL-2R antibodies in multiple sclerosis patients
EA050244B1 (ru) Способ диагностики in vitro рака желудка и способ мониторинга эффективности его лечения
HK1194999A (en) Methods of administering beta7 integrin antagonists
HK1190642A (en) Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects
HK1190642B (en) Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)